Vitalex is a start-up company created to further the development of technologies discovered in the laboratory of its founder, Dr Ashraf S. Ibrahim, a senior investigator at The Lundquist Institute at Harbor-University of California at Los Angeles (UCLA) Medical Center and a Professor at the David Geffen School of Medicine at UCLA. Vitalex has obtained > $ 10 million in non-dilutive funding from the National Institute of Allergy and Infectious Diseases (NIAID) to further the development of a dual antigen vaccine that targets hospital-acquired infections caused by multidrug resistant Candida albicans, Candida auris, and Gram-negative bacteria including those caused by Pseudomonas aeruginosa, Acinetobacter baumannii, and Klebsiella pneumoniae. Vitalex is also developing a humanized monoclonal antibody against the lethal and rare fungal infection, mucormycosis.